Pharmacological manipulation of N-methyl-D-aspartate (NMDA) receptors may be critical for the treatment of many neurological and psychiatric disorders. Metabotropic glutamate (mGlu5) receptors are abundant in corticolimbic circuitry, where they modulate NMDA receptor-mediated signal transduction. Therefore, pharmacological manipulation of mGlu5 receptor may provide a treatment strategy for cognitive disorders that are associated with NMDA receptor dysfunction. We sought to determine whether the recently described molecular and cellular interactions between NMDA and mGlu5 receptors coregulate higher order behaviors. We examined the interaction of the selective mGlu5 receptor antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and the use-dependent NMDA antagonist MK-801, on locomotion, stereotypy, working memory, instrumental learning, and corticolimbic dopamine release. MPEP, at 10 mg/kg, but not 3 mg/kg, impaired working memory and instrumental learning, transiently increased dopamine release in prefrontal cortex and nucleus accumbens, and augmented the effect of MK-801 on cortical dopamine release, locomotion, and stereotypy. Pretreatment with 3 mg/kg of MPEP enhanced the detrimental effects of MK-801 on cognition. These results demonstrate that an mGlu5 receptor antagonist can potentiate the motoric, cognitive, and dopaminergic effects of an NMDA receptor antagonist. Thus, mGlu5 receptors appear to play a major role in regulating NMDA receptor-dependent cognitive functions such as learning and working memory. By extension, these results suggest that pharmacological potentiation of mGlu5 receptors may ameliorate the cognitive and other behavioral abnormalities associated with NMDA receptor deficiency.
INTRODUCTION
N-methyl-D-aspartate (NMDA) receptors have been implicated in physiological and pathological processes, including brain development, neuroplasticity, excitotoxicity, neurodegeneration, and cognition. Thus, pharmacological modulation of NMDA receptor function has important clinical potential for the treatment of brain disorders including epilepsy, Alzheimer's disease, drug dependence, and schizophrenia (Kemp and McKernan, 2002) .
The recently identified metabotropic glutamate receptor (mGluR) family exemplifies the complexity of glutamatergic neurotransmission in the brain, and provides attractive targets for the development of glutamatergic ligands with increased specificity of action (Conn and Pin, 1997; Cartmell and Schoepp, 2000) . In the context of NMDA receptor-mediated neurotransmission, the mGlu5 subtype of mGluRs is of special interest. In vitro studies have suggested that activation of mGlu5 receptors, which are coupled via Gq to phospholipase C, can increase NMDAevoked responses in neural tissues including cortex (Doherty et al, 1997; Ugolini et al, 1997; Awad et al, 2000; Attucci et al, 2001; Mannaioni et al, 2001; Pisani et al, 2001) . The selective mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks NMDA-induced membrane depolarization in striatal spiny neurons and in cortical wedges (Pisani et al, 1997; Attucci et al, 2001) . Systemically administered mGlu5 and NMDA receptor antagonists produce similar anxiolytic (Spooren et al, 2000; Chojnacka-Wojcik et al, 2001) , neuroprotective (Bruno et al, 2000) , anticonvulsant (Chapman et al, 2000) , and tolerance blocking (Kozela et al, 2003) effects, and disrupt prepulse inhibition (Henry et al, 2002; Kinney et al, 2002) . Therefore, modulation of mGlu5 receptors may be an effective therapeutic strategy for manipulation of NMDA receptor-mediated neurotransmission in disorders such as schizophrenia (Tamminga, 1998; Goff and Coyle, 2001 ; Krystal et al, 2003; Moghaddam, 2003) and addiction (Wolf, 1998) , where NMDA receptor dysfunction is suspected.
The present study was undertaken to determine whether mGlu5 and NMDA receptors interact to regulate complex behaviors that are relevant to cognitive disorders such as schizophrenia. Our strategy focused on assessing whether the selective mGlu5 receptor antagonist, MPEP, mimics or exacerbates the effects of the NMDA receptor antagonist MK-801. In laboratory animals, NMDA receptor antagonist treatment produces a host of behavioral and neurochemical effects that are relevant to symptoms of schizophrenia (Geyer and Moghaddam, 2002) . Accordingly, we chose a wide range of clinically relevant measures including locomotion, stereotypy, spatial working memory, instrumental learning, and dopamine release in prefrontal cortex and nucleus accumbens.
MATERIAL AND METHODS

Subjects
Male Sprague-Dawley rats (Harlan, Somerville, NJ) weighing 300-350 g were housed two or three to a cage and maintained on a 12/12 h light/dark cycle (lights on at 0700). The rats had ad libitum access to food and water throughout the experiment, with the exception of the animals used in the operant learning experiments, which were placed on a restricted food diet of 15 g per day 1 week before the start of training. Animal care and experimental procedures were in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the Yale University Animal Care and Use Committee.
Microdialysis Procedure
Rats were anesthetized with halothane and placed in a stereotaxic frame with blunt ear bars. A small incision (7-10 mm) was made in the skin over the skull. The wound margin was infiltrated with lidocaine. Concentric microdialysis probes were implanted bilaterally into the medial PFC (anteroposterior (AP), þ 3.2; mediolateral (ML), þ 0.6; dorsoventral (DV), À5.3) and the NAc (AP, þ 1.8; ML, 1.0; DV, À8.4). All coordinates are relative to bregma and according to the atlas of Paxinos and Watson (1986) . Probes were secured into place with dental acrylic and anchored by skull screws. Immediately after surgery, the microdialysis probes were connected to a liquid swivel-balance arm assembly, and the rats were placed in a clear polycarbonate cage (44 Â 22 Â 42 cm 3 ) containing fresh bedding. The cages were placed in a quiet room with a 12 h light/dark cycle (lights on at 0700). Animals had ad libitum access to food and water, and were allowed to recover for 24 h prior to the collection of the dialysate samples. Experiments were performed in awake and freely moving animals. Microdialysis probes used had an outer diameter of 330 mm and exposed tips of 3.0 mm (for PFC) and 2.0 mm (for NAc). Probes were perfused with a Ringer's solution containing (in mM): 145 NaCl, 2.7 KCl, 1.0 MgCl 2 , and 1.2 CaCl 2 , at a flow rate of 0.5 ml/min during the recovery period and 2.0 ml/min during the experiment. Dialysis samples were collected every 20 min and injected immediately onto an HPLC system with electrochemical detection for the analysis of dopamine (Adams and Moghaddam, 1998) .
After the termination of each experiment, animals were anesthetized with chloral hydrate and perfused intracardially with saline followed by 10% buffered formalin. Brains were removed and stored in formalin. Serial sections of the fixed brains were stained with cresyl violet. Probe placement was verified for all the data sets used in this study.
Locomotor Activity and Stereotypy Rating
A data-acquisition system (Med Associates, St Albans, VT) was used to record horizontal locomotor activity during the microdialysis experiments. Four pairs of photocells spaced evenly along the length of the cage recorded the cumulative nonrepetitive beam breaks in 5 min time bins. These values were averaged across 20 min time bins corresponding to the dialysis data. Stereotypy during microdialysis experiments was rated as described previously (Adams and Moghaddam, 1998) . Specifically, animals were rated every 5 min and received a score of '0' for the absence or '1' for the presence of each of the following behaviors: ambulation, freezing, turning, grooming, sniffing, mouth movements, jaw tremor, head wagging, and rearing. Behaviors were scored as present if they were expressed for greater than 30 s. Stereotypy scores were calculated by averaging scores for each 20-min block of time for each rat.
Spontaneous Alternation Test
A four-arm radial maze (plus maze) was used to assess spontaneous alternation behavior, a measure of spatial working memory. This task is based on the tendency of rodents to preferentially explore the least recently visited arm of a multiarm maze (Kokkinidis and Anisman, 1976; Dember and Richman, 1989) . Spontaneous alternation performance is considered a measure of spatial working period memory, as performance is sensitive to delay and to extramaze spatial cues (Hooper et al, 1996; Dember and Richman, 1989; Ragozzino et al, 1996) .
The maze was constructed of Plexiglas (0.63 cm thick) and painted with gray primer. It consisted of a square central platform (14 Â 14 cm 2 ), to which four arms were joined. The arms were 14.0 cm wide, 40.6 cm long, and 12.7 cm high. Testing was performed in a room with distinct, extramaze, visual cues on the walls. Rats were handled for at least 5 days before spontaneous alternation testing. Spontaneous alternation testing was conducted by placing the rat on the center platform of the maze and allowing 12 min of unimpeded exploration. The number and sequence of arm entries were recorded for calculation of a percent alternation score. An alternation consisted of four different arm choices out of five consecutive arm entries. A 4/5 alternation score was computed by dividing the number of observed alternations in overlapping quintuplets by the number of possible alternations, and multiplying the quotient by 100.
Instrumental Learning Task
Operant chambers (Coulbourn Instruments, Allentown, PA) were equipped with a light illuminating the chamber (house mGlu5-NMDA receptor interaction H Homayoun et al light), three nosepoke modules, an illuminated food trough, and a food pellet delivery system. Nosepoke modules were placed on the wall opposite the food trough. Nosepoke modules could be illuminated by red light-emitting diodes, and the food trough could be illuminated by a white incandescent bulb. Head entries into the nosepoke modules or the pellet trough were detected by photosensors. A PCbased controller and data-acquisition software were used (Graphic State Notation, Coulbourn Instruments, Allentown, PA). Rats were habituated prior to training by being handled for 10 min for 2 days, and then exposed to the operant chambers for 3 consecutive days. The first day of exposure consisted of a 5 min session with the house light on and five food pellets (dextrose pellets, 45 mg, Bio-Serv, Frenchtown, NJ) in the food trough. The next 2 days of habituation exposure each consisted of a 10 min session during which house light was illuminated. After 15 s, one food pellet was released into the pellet trough, and the pellet trough light was illuminated. The pellet trough light remained on until the rat poked its head into the food trough, at which point started a new cycle, with the next food pellet drop occurring 20 s later. This procedure habituated the rats to the chamber and reward procedure before instrumental training began.
Rats were then trained on a continuous reinforcement schedule to nosepoke into an illuminated nosepoke module in order to receive a food reward. The training procedure consisted of 5 consecutive days, followed by a sixth day, with a 2-day interval between days 5 and 6. Each session lasted 20 min. The house light was continuously illuminated for the duration of the session. After a 15 s period (State1, S1), the center nosepoke module was illuminated with red light (S2). This light remained on until the first nosepoke into the illuminated nosepoke module, at which time the red light would go off, a food pellet would be delivered into the food trough, and the food trough light illuminated (S3). The food trough light remained on (S4) until a nosepoke into the food trough occurred, which initiated a new cycle, with the repeat of S2. Nosepokes into either of the nonilluminated modules were not rewarded. The number of correct choices was recorded as the total number of rewards delivered (food pellets released). The ratio of rewards delivered to the total number of nosepokes was recorded as a measure of choice accuracy.
Materials
MK-801 was obtained from Sigma (St Louis, MO). MPEP was purchased from Tocris Cookson or synthesized inhouse according to the method of Alagille et al (2003) . Both drugs were dissolved in distilled water vehicle and were injected intraperitoneally. The vehicle solution alone was used for control injections. All reagents for the HPLC mobile phase and the perfusion fluid were analytical grade and were obtained from Sigma.
Data Analysis
Microdialysis, locomotion, and stereotypy data were first analyzed by two-way, repeated measures ANOVA, with time as the repeated measure and drug treatment as the betweengroup measure. When significant main effects were found, further within-and between-group analyses were made using one-way ANOVA with Bonferroni-adjusted post hoc tests. Repeated measures ANOVAs were used for withingroup analyses. The spontaneous alternation data were analyzed by one-way ANOVA with Bonferroni-adjusted post hoc tests. Instrumental learning data were analyzed by twoway, repeated measures ANOVA, with test day as the repeated measure. Subsequent comparisons within and between groups were made using one-way ANOVAs with Bonferroni-adjusted post hoc tests. Repeated measures ANOVAs were used for within-group analyses. The level of significance was po0.05. Figure 1a shows the effects of systemic injection of MPEP (3 and 10 mg/kg) on dopamine release in the medial PFC. Twoway ANOVA with time as repeated measure showed Further analysis comparing the effect of each drug dose with its respective baseline value showed significant drug-induced increases in dopamine release (vehicle, F 10,40 ¼ 16.6; MPEP 3, F 10,60 ¼ 12.1, MPEP 10, F 10,60 ¼ 34.4, po0.001). Between-group post hoc comparisons showed that the increase in dopamine release after treatment with 10 mg/kg, but not 3 mg/kg, of MPEP was significantly different from that after vehicle treatment alone.
RESULTS
Microdialysis Experiments
In the nucleus accumbens, vehicle injection induced a mild, delayed increase in dopamine release (Figure 1b ). This increase was most probably a result of injection-associated stress. However, there were no significant main effects of either time or treatment.
In animals pretreated with vehicle, MK-801 (0.1 mg/kg) produced a significant increase in the medial PFC dopamine efflux that peaked 60 min after injection and remained elevated significantly above baseline up to 120 min after injection (Figure 2a ). When the effects of combined administration of MPEP and MK-801 were examined, there were significant effects of time (F 11,231 Further post hoc analysis showed that pretreatment with MPEP (10 mg/kg) augmented this effect of MK-801, leading to a significantly higher increase than that for the vehiclepretreated group alone. The combination of the low doses of MPEP (3 mg/kg) and MK-801 (0.01 mg/kg) induced a mild increase in PFC dopamine release that was significantly higher than baseline for 40 min after MK-801 injection, but was less potent than the effect of the high dose of MK-801 (0.1 mg/kg) alone.
In the nucleus accumbens (Figure 2b ), all three treatment groups showed a significant increase in dopamine release compared to their respective baseline levels (MPEP 3 þ MK-801 0.01, F 11,77 ¼ 6.55, po0.001; vehicle þ MK-801 0.1, F 11,77 ¼ 138.9.47, po0.001; MPEP 10 þ MK-801 0.1, F 11,77 ¼ 169.6, po0.001). However, post hoc analysis revealed that pretreatment with MPEP (10 mg/kg) had no significant additive effect on the MK-801 (0.1 mg/kg)-induced increase in nucleus accumbens dopamine release.
Locomotion and Stereotypy
MPEP (3 and 10 mg/kg) did not alter locomotor activity as compared to that of the vehicle group (Figure 3a ). There was a significant main effect of time (F 10,180 ¼ 170.45, po0.001), but not of drug treatment (F 2,18 ¼ 2.78, p40.05), nor was there a significant time Â treatment interaction (F 20,180 ¼ 1.44, p40.05). Post hoc analysis revealed that vehicle or MPEP induced a temporary increase in locomotor activity that returned to baseline level 40 min after injection. Figure 3b shows the effect of MK-801 alone or in combination with MPEP on locomotor activity. There were significant main effects for time (F 10,260 ¼ 36.8, po0 .001) and treatment (F 4,26 ¼ 416.37, po0.001), and a significant time Â treatment interaction (F 40,260 ¼ 23.56, po0.001) . Further analysis with one-way ANOVA with time as repeated measure showed that all treatments in this experiment significantly changed locomotor activity compared to respective baseline activity levels (vehicle þ vehicle, F 10,60 ¼ 21.58, po0.001; MPEP 3 þ MK-801 0.01, In vehicle pretreated animals, MK-801 (0.1 mg/kg) significantly increased locomotion over that observed in the control group. This effect of MK-801 was significantly potentiated by pretreatment with MPEP (10 mg/kg) (Figure 3b) . Post hoc analysis showed that the combination Figure 4a demonstrates the effect of MPEP on stereotypy. There was a significant main effect of time (F 10,180 ¼ 7.75, po0.001), but not of treatment (F 2,18 ¼ 1.0, p40.05). There was also a significant time Â treatment interaction (F 20,180 ¼ 2.29, po0.005). Further post hoc analysis showed that injection of either vehicle or the low dose of MPEP induced a temporary increase in stereotypy scores. The group treated with the higher dose of MPEP did not show this injection-induced stereotypy.
MK-801 (0.1 mg/kg) produced a sustained increase in stereotypy that peaked 40 min after injection and returned to baseline 2 h after injection (Figure 4b ). There were significant main effects of time ( 
Spontaneous Alternation Test of Working Memory
Treatment with MPEP and MK-801 significantly affected both alternation score (F 6,60 ¼ 21.25, po0.001) and the 
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total number of arm entries (F 6,60 ¼ 7.98, po0.001). Post hoc analyses showed that injection of MPEP, 60 min before testing, impaired spontaneous alternation behavior in a dose-dependent manner, with 10 mg/kg, but not 3 mg/kg, impairing performance relative to vehicle-injected controls (Figure 5a ). MK-801 (0.01 and 0.1 mg/kg), injected 40 min before testing, also affected spontaneous alternation behavior in a dose-dependent manner, with 0.01 mg/kg significantly enhancing and 0.1 mg/kg significantly impairing performance relative to that of the vehicle-injected control group (Figure 5a ). The coadministration of MPEP and MK-801, at low doses which alone did not impair performance, significantly impaired alternation performance, as compared to that of the control group, or that of the respective groups receiving MPEP alone. The impairment induced by the combined low doses of the two drugs was significantly different from the effect of the low dose of MK-801 alone. The impairment due to the combined administration of the high doses of MPEP and MK-801 was not significantly different from that induced by the high dose of MK-801 alone. It is likely that this latter result was due to a floor effect; performance impairments following treatment with the higher doses of either MPEP or MK-801 alone neared chance level.
A comparison of the arm entries made during the 12 min test period between the above groups showed that only the two groups that received 0.1 mg/kg of MK-801 (with either vehicle or MPEP 10 mg/kg pretreatment) made significantly more arm entries during alternation task, relative to vehicle-injected controls (Figure 5b ).
Instrumental Learning
Rats in the vehicle-injected control group learned to associate responding at the center, lighted nosepoke hole with delivery of a food reward. They significantly increased the number of correct choices per session across days, reaching an asymptotic performance level by the third day of testing (Figure 6a ). There were significant main effects of test day (F 5,155 (Figure 6a ), the combination of these two doses significantly decreased the number of rewards received on test days 2-5, compared to the vehicle/ vehicle control group. In the combined low-dose group, the number of correct choices was also significantly lower Figure 5 Effects of MPEP and MK-801 on spontaneous alternation behavior. MPEP or vehicle were administered 60 min before test and MK-801 or vehicle were administered 40 min before test. (a) MPEP at 10 mg/kg (but not at 3 mg/kg) and MK-801 at 0.1 mg/kg significantly decreased percent alternation scores relative to vehicle-injected control rats. MK-801 at 0.01 mg/kg significantly enhanced the alternation performance. The administration of MPEP in combination with MK-801 significantly impaired alternation performance, at both low and high combined doses of MPEP and MK-801. These impairments were significant compared to both the vehicle/vehicle group and to the respective groups receiving MPEP/vehicle. The performance of the combined lowdose group (but not the combined high-dose group) was also significantly different from the corresponding vehicle/MK-801 group. Data are expressed as mean7SEM of percent alternation scores in each group. (b) Treatment with MK-801 (0.1 mg/kg), alone or in combination with MPEP (10 mg/kg), significantly increased the total number of maze arm entries during the 12 min test period, compared to the control group. None of the other groups differed significantly from control in the number of arm entries. Data are expressed as mean7SEM of total arm entries in each group. *Significant differences from the vehicle/vehicle group. þ Significant difference from the corresponding MPEP/vehicle group. # Significant difference from the vehicle/MK-801 0.01 mg/kg group.
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H Homayoun et al than in the groups pretreated with the low dose of either MK-801 or MPEP alone on each of the first 3 days of training. Across the final 3 days of testing, when all groups received only vehicle injections, the combined low-dose group significantly improved its performance, reaching the performance level of the control group on the sixth day. As would be expected, the high-dose MK-801 produced anomalous effects on operant performance, presumably because of enhancing actions on motor activity and stereotypy. The analysis of correct choices in groups treated with the higher doses of MPEP and MK-801 (Figure 6b ) revealed significant main effects of day (F 5,155 ¼ 73.38, po0.001) and treatment (F 3,31 ¼ 9.8, po0.001), and a significant day Â treatment interaction (F 15,155 ¼ 5.09, po0.01). All treatment groups significantly increased the number of correct choices across days (vehicle þ MK-801 0.1, F 5,40 ¼ 8.2, po0.001; MPEP 10 þ vehicle, F 5,40 ¼ 27.8.0, po0.001; MPEP 10 þ MK-801 0.1, F 5,30 ¼ 22.89, po0.001). Post hoc comparisons revealed that at the outset of testing, the high-dose MK-801 group had a slight, nonsignificant, increase in the number of correct choices on the first day ( Figure 6b) . However, the learning curve of this group was statistically flat across the first 3 days of testing, and by test day 3 they were performing significantly worse than the control group. Rats treated with a high dose of MPEP, alone or in combination with MK-801, performed significantly worse than those in the vehicle group. The impairment induced by the combination of the higher doses of MPEP and MK-801 was not significantly larger than the MPEP (10 mg/kg) group, again most likely because of floor effects on performance.
The synergistic effect of the low doses of MK-801 and MPEP was also evident when data were analyzed as the ratio of correct to total nosepokes (Figure 7a ). (Note that the high dose MK-801 data were also anomalous using this analysis; they are therefore not shown or discussed further.) There were significant main effects of day (F 5,155 ¼ 10.19, po0.001) and treatment (F 3,31 ¼ 4.82, po0.01), and a significant day Â treatment interaction (F 15,155 ¼ 3.89, po0.001). Further analysis showed that rats in all treatment groups in this experiment significantly increased their respective correct/total ratios across test days (vehicle þ vehicle, F 5,45 ¼ 6.59, po0.001; vehicle þ MK-801 0.01, F 5,30 ¼ 3.5, po0.05; MPEP 3 þ vehicle, F 5,40 ¼ 2.98, po0.05; MPEP 3 þ MK-801 0.01, F 5,40 ¼ 10.65, po0.001). Further post hoc comparisons between groups showed that during the first 3 days of training, treatment with the low doses of MK-801 (0.01 mg/kg) or MPEP (3 mg/kg) led to correct/ total nose pokes ratios comparable to vehicle/vehicle treatment. However, when administered in combination, these low doses significantly decreased the ratio of correct/total choices compared to either the vehicle/vehicle group or groups treated with only one of the two drugs. The response ratio reached the control level only on the second day of the drug-free period (test day 5). The analysis of the total number of nose pokes showed significant main effects of day (F 5,155 ¼ 50.96, po0.001) and treatment (F 3,31 ¼ 4.45, p ¼ 0.01), without a significant day Â treatment treatment interaction (F 15,155 ¼ 1.31, p40.05). Post hoc analysis showed that, on each of the first 3 days of training, the total number of nosepokes made by the low-dose MK-801-and MPEP-treated groups, respectively, were comparable to the number made by the vehicle/vehicle group (Figure 7b ). 
DISCUSSION
The present study demonstrates a functional interaction between NMDA and mGlu5 receptors on several diverse measures of behavior. At high doses, the mGlu5 receptor antagonist MPEP mimicked the effects of the NMDA antagonist MK-801 to increase dopamine release and impair cognition. MPEP, at a low dose, which by itself had no significant effects on behavior, potentiated the effects of MK-801. Specifically, pretreatment with MPEP enhanced the magnitude of MK-801-induced hyperlocomotion, increased the duration of MK-801-induced stereotypy, and enhanced MK-801-induced impairments of spatial working memory and instrumental learning. These findings suggest that mGlu5 receptors modulate NMDA receptor-mediated control of high-level functions such as learning and working memory.
The activation of mGlu5 receptors leads to postsynaptic excitatory effects and potentiation of NMDA currents (Bleakman et al, 1992; Conn and Pin, 1997; Bordi and Ugolini, 1999; Awad et al, 2000) . NMDA receptors follow a complex mode of regulation, as their activation is voltage dependent, requires additional ligand binding, and is influenced by a number of modulatory sites. Thus, interaction between mGlu5 and NMDA receptors likely occurs through several mechanisms, including slow changes in membrane potential (Morisset and Nagy, 1996) , activation of protein kinase C with subsequent increase in intracellular Ca 2 þ (Conn and Pin, 1997; Benquet et al, 2002) , or interactions with intracellular Homer proteins (Ango et al, 2001) . Moreover, a positive modulatory autoreceptor role has been also described for mGlu5 receptors (Thomas et al, 2001) .
Several recent observations have predicted that agonists and antagonists of mGlu5 receptors may, respectively, attenuate and potentiate the effects of NMDA antagonists in vivo. For example, there is an interaction between mGlu5 and NMDA receptor antagonists on morphine antinociceptive tolerance (Kozela et al, 2003) , phencyclidine-induced hyperlocomotion, and disruption of prepulse inhibition (Henry et al, 2002; Kinney et al, 2002 Kinney et al, , 2003 . Together with the present data, these studies suggest that selective modulation of glutamatergic transmission through mGlu5 receptors can be used as a pharmacological strategy for the treatment of brain disorders that involve NMDA receptor dysfunction. The lack of motoric effects of MPEP is important in this context because it suggests that agonists of mGlu5 receptor may enhance learning and memory without affecting motor behaviors.
Schizophrenia is an important example of a disorder in which NMDA receptor dysfunction has been implicated (Tamminga, 1998; Harrison and Owen, 2003; Moghaddam, 2003; Coyle, 1996) . Antagonists of NMDA receptors exacerbate pre-existing symptoms in patients with schizophrenia (Luby et al, 1959; Lahti et al, 1995; Malhotra et al, 1997) , and produce schizophrenia-like symptoms in healthy individuals (Javitt and Zukin, 1991; Krystal et al, 1994) . Thus, NMDA receptor hypofunction has been implicated in the pathophysiology of this disease (Olney and Farber, 1995) , suggesting that augmentation of NMDA receptor function may be a plausible therapeutic strategy for the treatment of some symptoms of schizophrenia (Javitt et al, 1994; Coyle et al, 2002; Moghaddam, 2003) . The present findings suggest that potentiation of mGlu5 receptor function may be a novel strategy, at least for the treatment of working memory impairments and other cognitive deficits associated with schizophrenia.
The cognitive impairment induced by MPEP is in agreement with the previous reports of mGlu5 receptor involvement in working and long-term memory, as measured by task performance in the eight-arm radial and Y-mazes (Lu et al, 1997; Balschun et al, 1999; Balschun and Wetzel, 2002; Manahan-Vaughan and Schuetz, 2002) . In the Figure 7 Effects of combined lower doses of MPEP (3 mg/kg) and MK-801 (0.01 mg/kg) on the correct/total nosepokes ratio and total number of nosepokes in the instrumental learning task. (a) Neither MPEP (3 mg/kg) nor MK-801 (0.01 mg/kg) alone altered the correct/total nosepokes ratio compared to vehicle/vehicle group. However, the combination of the low doses of MPEP (3 mg/kg) and MK-801 (0.01 mg/kg) significantly decreased the correct/total nosepokes ratio compared to other groups. Data are expressed as group means7SEM of the ratio of correct nosepokes to total nosepokes during each session. (b) There were no significant differences in the total number of nosepokes between drug-treated groups and vehicle/ vehicle controls during the first 3 days of training.
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H Homayoun et al present study, antagonism of mGlu5 receptors with MPEP alone (at 10 mg/kg) impaired both working memory and instrumental learning. The low dose of MPEP (3 mg/kg) did not impair cognitive performance, but showed an additive effect with the lower dose of MK-801, impairing performance on both tasks. The combined high doses of MPEP and MK-801 induced a profound performance impairment that was not significantly different from the effect of the high dose of MPEP or MK-801 alone. This may be due to a 'floor' effect of the high dose of MK-801. Nonetheless, because of the motor side effects of the high dose of MK-801, interpretation of these results is problematic. The lowdose data are, however, conclusive in demonstrating a synergistic effect of these two antagonists on spatial working memory and on instrumental learning. It should be noted that although mGlu5 receptors may be involved in some drug-related motivational behaviors (Paterson et al, 2003) , the observation that mGlu5 receptor knockout mice have intact levels of food-reinforced lever pressing behavior despite a reduced tendency to self-administer cocaine (Chiamulera et al, 2001 ) makes it unlikely that altered motivation is responsible for the impaired performance of MPEP-treated animals in the appetitively motivated instrumental learning task used here. The effect of MPEP alone on PFC and NAc dopamine release was similar to that observed with MK-801 and other NMDA receptor antagonists (Verma and Moghaddam, 1996; Adams and Moghaddam, 1998) in that a larger increase was observed in the PFC than the NAc. MPEP also mimicked the effect of MK-801 on cortical dopamine release without any effect of its own on locomotion or stereotypy. While the link between the effects of these compounds on cortical dopaminergic transmission and behavior remains elusive, evidence supports a significant relationship. Prefrontal dopamine is an important modulator of working memory (Sawaguchi and Goldman-Rakic, 1991) and instrumental learning (Baldwin et al, 2000 (Baldwin et al, , 2002 . While dopamine release is necessary for proper mnemonic function, excessive prefrontal dopamine release, such as that induced by NMDA antagonists (Verma and Moghaddam, 1996) , can also impair cognitive performance (Arnsten et al, 1994) . The expression of mGlu5 receptors is abundant in cortical and limbic regions (Shigemoto et al, 1993; Romano et al, 1995) , which are critical sites for the regulation of working memory and learning. Thus, it is tempting to speculate that the activation of dopamine release by MPEP is in part responsible for its behavioral effects. However, the combination of the lower doses of MPEP and MK-801 that produced cognitive impairments and stereotypy in the present study did not significantly increase cortical dopamine release, suggesting a possible dissociation between their effects on dopamine release and cognitive and motoric impairments. This is in agreement with numerous other studies, suggesting that corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of NMDA antagonists (Hoffman et al, 1993; Ogren and Goldstein, 1994; Steinpreis et al, 1994; Carlezon and Wise, 1996; Moghaddam, 1998, 2001 ).
In conclusion, the present study reports a functional interaction between mGlu5 and NMDA receptor antagonists, influencing not only locomotion and stereotypy but also learning and working memory, cognitive functions that are impaired in many neurological and psychiatric disorders. The results of our studies complement the molecular and cellular data on NMDA and mGlu5 receptor interactions, which collectively predict that in disorders where NMDA dysfunction is suspected, pharmacological manipulation of mGlu5 receptors would be of therapeutic use.
